Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Directors were buying at 80p and this hit 150p on FDA approval. Patent protected until 2035 in a 100 billion dollar liquid biopsy field.
Angle can do 50,000 tests per year in its laboratories and at an average of £1000 per test. Then there is also sales of the machines and ancillary equipment. You do the maths. Truely staggering. Dyor
Big Pharma can not ignore this...
Amazing results. Shows power of Parsortix.
"Actionable variants identified in our patient cohort in the CTCs that were not present in the ctDNA included variants targeted by widely used drugs from many large pharma companies, for example:
-- PIK3CA (E545K): Alpelisib (Piqray(R) ) marketed by Novartis
-- EGFR (T790M): Tagrisso (Osimertinib(R) ) marketed by Astra Zeneca
-- ESR1 (K303R): Elacestrant (Oserdu(R) ) marketed by Menarini
-- MTOR (T1977K): Everolimus (Afinitor(R) ) marketed by Novartis
-- ERBB2 (R678Q): Trastuzumab, Pertuzumab, Neratinib, Afatinib marketed respectively by Astra Zeneca, Roche Genentech, Puma Biotechnology, and Boehringer Ingelheim